282529-08-2

Upstream product

• 106-93-4 ethylene dibromide 
• 282529-07-1 methyl 3-methyl-2-{2-(4-nitrobenzenesulfonamido)-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propanamido}butanoate 
• 282529-05-9 methyl 2-(2-{[(9H-fluoren-9-yl)methoxycarbonyl]amino}-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propanamido)-3-methylbutanoate 
• 109425-51-6 Fmoc-His(Trt)-OH 
• 6306-52-1 L-valine methylester hydrochloride 

Downstream Products

• 282529-12-8 methyl 3-methyl-2-(2-oxo-4-[(5-oxopyrrolidin-2-yl)carbonyl]-3-{[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl}piperazin-1-yl)butanoate 
• 282529-13-9 3-methyl-2-(2-oxo-4-[(5-oxopyrrolidin-2-yl)carbonyl]-3-{[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl}piperazin-1-yl)butanamide 
• 282529-10-6 methyl 3-methyl-2-(2-oxo-3-{[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl}piperazin-1-yl)butanoate 

Relevant academic research and scientific papers

Synthesis of a novel thyrotropin releasing hormone (TRH) analog incorporating a piperazin-2-one ring

The synthesis of a Thyrotropin Releasing Hormone (TRH) analog incorporating a piperazin-2-one ring is described. This conformationally restricted peptidomimetic attempts to retain the key recognition elements of the interaction between TRH and its receptor. The synthesis started from the protected dipeptide 2 and proceeded via the 4-nitrobenzenesulfonyl-activated intermediate 3, which was then cyclized, N-acylated, and deprotected to yield the target compound 1.